Astellas Closes California Facility; Takeda Expands ADHD Drug Production Amid Generic Competition

Astellas Facility Closure:
Astellas Gene Therapies is closing its biomanufacturing facility in South San Francisco, California, affecting approximately 100 employees.

Takeda's ADHD Drug Production:
Takeda can increase production of its ADHD drug Vyvanse, despite facing generic competition after its patent expired in August 2023.

Generic Competition:
The FDA has approved several generic versions of Vyvanse, which could help address the ongoing shortage of the drug in the U.S..

Takeda's Restructuring:
Takeda is also undergoing restructuring, including cutting 1,000 U.S. jobs and closing its San Diego research and development center by the end of September 2024.

Joint Venture:
Takeda, Astellas, and Sumitomo Mitsui Banking have announced a joint venture to incubate early drug discovery programs, primarily originating from Japan.